Orchard Therapeutics plc
NASDAQ: ORTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Hubert Baburaj Gaspar
- Employees
- 166
- Headquarters
- London, United Kingdom
- IPO year
- 2018
- Market cap
- $380.1M
- Website
- https://www.orchard-tx.com
Loading ORTX…
Loading profile data…Frequently asked questions about ORTX
What does Orchard Therapeutics plc (ORTX) do?
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a thera...
Where does ORTX trade?
Orchard Therapeutics plc (ORTX) trades on the NASDAQ Global Select.
What sector is ORTX in?
Orchard Therapeutics plc (ORTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Orchard Therapeutics plc?
Hubert Baburaj Gaspar is the chief executive officer of Orchard Therapeutics plc (ORTX).
Where is Orchard Therapeutics plc headquartered?
Orchard Therapeutics plc is headquartered in United Kingdom.
Does ORTX pay a dividend?
Orchard Therapeutics plc (ORTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ORTX go public?
Orchard Therapeutics plc (ORTX) completed its initial public offering in 2018.
Is ORTX an ADR?
Yes — ORTX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Orchard Therapeutics plc reporting and dividends follow the underlying issuer.